Drugs /

aromatase inhibitor

Back to Drugs List
Associated Genetic Biomarkers
Associated Diseases

Overview

NCI Definition [1]:
Any substance that inhibits aromatase, an enzyme responsible for the conversion of cholesterol to pregnenolone and the peripheral aromatization of androgenic precursors into estrogens. Inhibition of aromatase results in the suppression of estrogen-regulated processes.

Biomarker-Directed Therapies

Clinical Trials

View Clinical Trials for aromatase inhibitor

Aromatase inhibitor has been investigated in 12 clinical trials, of which 8 are open and 4 are closed. Of the trials investigating aromatase inhibitor, 1 is early phase 1 (0 open), 3 are phase 1 (1 open), 6 are phase 2 (5 open), and 2 are phase 3 (2 open).

ER Expression, ER Positive, and PR Expression are the most frequent biomarker inclusion criteria for aromatase inhibitor clinical trials.

Breast carcinoma and breast adenocarcinoma are the most common diseases being investigated in aromatase inhibitor clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Aromatase Inhibitor
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Aromatase Inhibitor
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating aromatase inhibitor and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
estrogen synthase inhibitor, aromatase inhibitor (substance), androstenedione aromatase inhibitor, aromatase inhibitor, aromatase inhibitor, estrogen synthetase inhibitor, inhibitors, aromatase, aromatase inhibitor (product), aromatase inhibitors
Drug Target(s) [2]:
CYP19A1
NCIT ID [1]:
C1740
SNOMED ID [1]:
C-78114

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.